Jan A. Burger, MD, PhD, MD Anderson Cancer Center, discusses "Outcomes of First-Line Ibrutinib in Patients with CLL/SLL and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE)."

Dr Linden shares encouraging results from the AMEERA-1 trial on SAR439859, an oral estrogen receptor degrader, for ER+/HER2- metastatic breast cancer, presented at the virtual 2020 SABCS Annual Meeting.

In this podcast, Andreas Hochhaus, MD, University Medical Center Jena, Germany, discusses the significance of the ASCEMBL trial presented at the virtual 2020 ASH Annual Meeting and Exposition, and proposes the question of how to eliminate persisting leukemic stem cells (LSCs) in chronic myeloid leukemia (CML).

In this podcast, Andreas Hochhaus, MD, University Medical Center Jena, Germany, discusses the use of asciminib versus bosutinib for the treatment of patients with chronic myeloid leukemia in chronic phase (CML-CP) previously given ≥2 tyrosine kinase inhibitors (TKIs). These data were presented at the virtual 2020 ASH Annual Meeting and Exposition.

In this video, Dr Raje discusses the clinical significance of anti-BCMA CAR-T therapy with bb2121 in patients with relapsed or refractory MM.

Dr Leonard Shares Highlights to Expect at the 2020 Leukemia, Lymphoma & Myeloma Congress by HMP Global

Episode 4: Evolving Therapies in Ewing Sarcoma by HMP Global

Abhishek Maiti, MD, Talks 10-Day Decitabine Plus Venetoclax for Intensive Chemo–Ineligible AML by HMP Global

Dr Nagourney on CRC Cells Treated with FOLFOX or CAPOX by HMP Global

Abdul Rahman Jazieh, MD, MPH, National Guard Health Affairs, Riyadh, Saudi Arabia, discusses a study on the presence of ALK+ NSCLC in the Middle East and North Africa, presented at the ESMO 2020 Virtual Congress.